Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Trends in Cancer Research   Volumes    Volume 15 
Phase I study evaluating vorinostat combined with paclitaxel and thoracic radiotherapy for inoperable stage III non-small cell lung cancer
Shilpen Patel, Laurie L. Carr, Libby Kell, Keith D. Eaton, Brenda F. Kurland, Renato G. Martins
Pages: 27 - 31
Number of pages: 5
Trends in Cancer Research
Volume 15 

Copyright © 2020 Research Trends. All rights reserved

Radiation and cisplatin-based chemotherapy constitute the standard treatment for locally advanced non-small cell lung cancer (NSCLC); however the prognosis of patients unable to tolerate cisplatin is poor. Recent pre-clinical studies have demonstrated the histone deacetylase (HDAC) inhibitor, vorinostat, enhances radiosensitivity of non-small cell cancer cell lines, and offers the potential of low toxicity and a novel mechanism of efficacy. This phase I clinical trial combines a therapeutic combination of vorinostat with paclitaxel and radiation therapy (RT) for the treatment of NSCLC, in a treatment combination not previously described. This phase I trial was an open-label, dose-escalating study to establish the maximum tolerated dose of vorinostat when given with concurrent chemotherapy and radiotherapy. The first patient cohort received a starting dose of 200 mg/day, taken 5 days a week, during radiotherapy. The dose was to be increased in the following patient cohorts until the maximum tolerated dose (MTD) was reached. Patients were administered concurrent paclitaxel at a dose of 60 mg/m2 and RT at 1.8 Gy per day to a total dose of 63 Gy. Between July 2008 and September 2009, 5 patients were enrolled on this study. Four of five patients enrolled completed the planned treatment. Although most patients were able to complete the study therapy, many experienced grade 3+ toxicities. A dose-limiting toxicity triggered the expansion of the 200 mg vorinostat cohort to six patients. Due to slow accrual and significant toxicities, the investigators and the sponsor decided to close the study in July, 2010. There is a strong need to investigate better therapeutic options for patients with NSCLC who cannot receive cisplatin. This patient population is growing and should not be overlooked even though their disease process poses significant challenge for trials.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms